Vertex Pharmaceuticals IncorporatedVRTX Vertex Pharmaceuticals Incorporated fair value $428–$722

Vertex is a highly profitable, mature compounder with a dominant franchise in cystic fibrosis generating massive free cash flowFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics.. The next phase of growth relies on successfully commercializing its pipeline, including CASGEVY for sickle cell disease and novel pain treatments.

• Cystic fibrosis therapeutics monopoly with
  Cystic fibrosis therapeutics monopoly with high switching costs and IP protection
• Specialized distribution and manufacturing scale
  Specialized distribution and manufacturing scale
• Cycle upside
  Biotech expansion phase driven by favorable FDA approvals, loose capital access, and premium valuations assigned to de-risked late-stage assets.